NCT02402764 2020-09-11Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)H. Lee Moffitt Cancer Center and Research InstitutePhase 2 Completed10 enrolled 7 charts